Abstract

The differential diagnosis among the commonest peripheral T-cell lymphomas (PTCLs; ie, PTCL not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, with the morphologic and phenotypic features largely overlapping. We performed a phase III diagnostic accuracy study to test the ability of gene expression profiles (GEPs; index test) to identify PTCL subtype. We studied 244 PTCLs, including 158 PTCLs NOS, 63 AITLs, and 23 ALK-negative ALCLs. The GEP-based classification method was established on a support vector machine algorithm, and the reference standard was an expert pathologic diagnosis according to WHO classification. First, we identified molecular signatures (molecular classifier [MC]) discriminating either AITL and ALK-negative ALCL from PTCL NOS in a training set. Of note, the MC was developed in formalin-fixed paraffin-embedded (FFPE) samples and validated in both FFPE and frozen tissues. Second, we found that the overall accuracy of the MC was remarkable: 98% to 77% for AITL and 98% to 93% for ALK-negative ALCL in test and validation sets of patient cases, respectively. Furthermore, we found that the MC significantly improved the prognostic stratification of patients with PTCL. Particularly, it enhanced the distinction of ALK-negative ALCL from PTCL NOS, especially from some CD30+ PTCL NOS with uncertain morphology. Finally, MC discriminated some T-follicular helper (Tfh) PTCL NOS from AITL, providing further evidence that a group of PTCLs NOS shares a Tfh derivation with but is distinct from AITL. Our findings support the usage of an MC as additional tool in the diagnostic workup of nodal PTCL.

Highlights

  • Peripheral T-cell lymphomas (PTCLs) represent 10% to 15% of all lymphomas, and their incidence is higher in Asia than in Western countries.[1]

  • We found that the molecular classifiers (MCs) significantly improved the prognostic stratification of patients with PTCL

  • Our findings support the usage of an MC as additional tool in the diagnostic workup of nodal PTCL

Read more

Summary

Introduction

Peripheral T-cell lymphomas (PTCLs) represent 10% to 15% of all lymphomas, and their incidence is higher in Asia than in Western countries.[1] They include several different entities[1]; four main subtypes (ie, PTCL not otherwise specified [NOS], angioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL; ALK negative and ALK positive]) represent approximately 75% of all patient cases in Europe and the United States.[1] The diagnosis of PTCL is usually challenging, requiring expertise in hematopathology. ALK-negative ALCL and PTCL NOS are characterized by a different prognosis,[3] and distinct therapeutic approaches have been proposed.[4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call